Ascendis Pharma A/S (NASDAQ:ASND) Given Average Rating of “Buy” by Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received an average recommendation of “Buy” from the seventeen research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $256.7333.

ASND has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, November 26th. Wedbush restated an “outperform” rating and issued a $220.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, November 18th. Wall Street Zen downgraded Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Wolfe Research began coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, November 18th. They issued a “peer perform” rating and a $255.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their target price on shares of Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an “overweight” rating in a report on Thursday, October 9th.

Ascendis Pharma A/S Stock Up 1.0%

Shares of ASND opened at $211.02 on Thursday. Ascendis Pharma A/S has a 52-week low of $118.03 and a 52-week high of $229.94. The company has a 50-day simple moving average of $206.14 and a 200-day simple moving average of $194.43. The company has a market capitalization of $13.07 billion, a PE ratio of -47.53 and a beta of 0.45.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The business had revenue of $250.71 million for the quarter, compared to the consensus estimate of $246.91 million. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ASND. Advisory Services Network LLC acquired a new position in shares of Ascendis Pharma A/S in the third quarter worth $26,000. Compagnie Lombard Odier SCmA purchased a new stake in shares of Ascendis Pharma A/S in the second quarter valued at $39,000. First Horizon Advisors Inc. purchased a new stake in Ascendis Pharma A/S in the 2nd quarter valued at about $41,000. Jones Financial Companies Lllp grew its holdings in Ascendis Pharma A/S by 57.2% in the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 83 shares during the period. Finally, Hantz Financial Services Inc. increased its position in Ascendis Pharma A/S by 291.1% during the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 262 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.